^
    1d
    Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. (PubMed, Am J Hematol)
    Here we report red blood cell (RBC) transfusion response analysis based on somatic mutations profile and disease risk for patients treated with luspatercept or epoetin alfa in the COMMANDS trial. Luspatercept represents an effective treatment option in various mutational backgrounds in LR MDS. Trial Registration: ClinicalTrials.gov Identifier: NCT03682536.
    Journal
    |
    SF3B1 (Splicing Factor 3b Subunit 1)
    |
    SF3B1 mutation
    |
    Reblozyl (luspatercept-aamt)
    5d
    A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) (clinicaltrials.gov)
    P3, N=46, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Nov 2025
    Trial completion • Trial completion date
    |
    Winrevair (sotatercept-csrk)
    6d
    Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    lenalidomide • pomalidomide • Winrevair (sotatercept-csrk)
    10d
    Matrix-Modulating pH-Gated Hydrogel for Coordinated Regulation of Cancer-Associated Fibroblast Phenotype and Mn²⁺-STING Activation for Enhanced Tumor Immunotherapy. (PubMed, Acta Biomater)
    This dynamic network, constructed by Schiff base crosslinking between carboxymethyl chitosan and aldehyde-functionalized hyaluronic acid, was utilized for the co-delivery of pirfenidone (PFD) and manganese-curcumin nanoparticles (MC)...This coordinated cascade elicits robust T-cell activation and cytokine secretion, achieving near-complete tumor eradication in murine melanoma models. Overall, this study establishes a therapeutic paradigm that integrates stromal barrier modulation with immune activation to achieve more effective tumor treatment.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STING (stimulator of interferon response cGAMP interactor 1)
    11d
    Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib (clinicaltrials.gov)
    P1, N=24, Completed, PureTech | Not yet recruiting --> Completed
    Trial completion
    |
    nintedanib
    11d
    Effect of Pirfenidone on TA Fibrosis (clinicaltrials.gov)
    P4, N=92, Not yet recruiting, Shanghai Zhongshan Hospital
    New P4 trial
    |
    IL17A (Interleukin 17A)
    14d
    A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Takeda
    New P2 trial
    |
    elritercept (KER-050)
    15d
    Study of ZGGS18 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=222, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    ZGGS18
    15d
    Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ZGGS18 • nilvanstomig (ZG005)
    15d
    Clinical Applications of Ligand Traps Targeting Activin Type II Receptors. (PubMed, Antiinflamm Antiallergy Agents Med Chem)
    Two peptide-based ligand traps have recently received clinical approval: luspatercept [ActRIIB-Fc], an erythroid maturation agent, and sotatercept [ActRIIA-Fc], a novel therapeutic agent for pulmonary arterial hypertension [PAH]. Although both agents have failed to increase skeletal muscle mass in clinical trials consistently, they represent significant advances in the treatment of hematopoietic and vascular disorders. Future studies should focus on optimal dosing strategies, long-term safety, and potential synergistic effects when combined with other therapeutic modalities.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • ACVR2A (Activin A Receptor Type 2A) • ACVR2B (Activin A Receptor Type 2B)
    |
    Reblozyl (luspatercept-aamt) • Winrevair (sotatercept-csrk)